Researchers to develop new diagnostic test for Chagas disease

by James Hataway
A UGA faculty member since 1984, Rick Tarleton is the founding director of the Center for Tropical and Emerging Global Diseases.

(Medical Xpress)—Researchers at the University of Georgia will soon begin a study designed to identify new ways of determining treatment efficacy in Chagas disease, a potentially fatal tropical disease that infects approximately 8 million people worldwide and is the leading parasitic killer in the Americas.

There is currently no easy-to-use and reliable test available to assess if Chagas patients receiving treatment are rid of the parasite that causes the disease, . This project will access the performance of commonly prescribed anti-parasitic drugs and hopefully lead to a new, efficient to detect the parasite.

"The major problem in terms of drug treatment for Chagas disease is that it is virtually impossible to determine if the treatment is effective," said Rick Tarleton, Distinguished Research Professor in the Franklin College of Arts of Sciences department of , and member of UGA's Center for Tropical and Emerging Global Diseases. "The detection of T. cruzi is very difficult because of low parasite numbers and the fact that these are primarily in deep tissues such as the heart."

In the first-ever large-scale study, Tarleton will team up with researchers at the Texas Biomedical Research Institute to study treatment of non-human primates that have become infected with the parasite in their outdoor living environment. The animals will be treated with three versus placebo, and a series of blood tests will search for evidence of infection in the blood.

The results from this project have the potential to significantly improve current treatments, but also to open the doors for new, more advanced drugs.

"There are several existing compounds that are available for use in the treatment of Chagas disease, but they are not frequently used because there is not an acceptable test to tell if they actually worked," Tarleton said. "So the drugs go unused and people die."

Major are also hesitant to invest in drug discovery because they have no way of determining whether their drugs work, or if they are better than existing drugs.

Chagas disease is the leading cause of death among young-to-middle-age adults in endemic areas of South America, and many people live years without symptoms while their hearts and digestive systems suffer irreparable damage.

The T. cruzi parasite is most often spread via a subspecies of blood-feeding insects called triatomines. These insects, commonly known as "kissing bugs" because they tend to bite people on the face and lips, feed and defecate on the skin. Triatomine feces containing the parasite are then rubbed into the bite when humans or animals scratch the wound, rub their eyes or touch their mouths.

Once confined almost exclusively to Latin America, has spread throughout the world. In the United States, the Centers for Disease Control and Prevention estimate 300,000 or more people are infected, and it is becoming increasingly common in domesticated dogs and wild animals.

The current project, made possible by support from The Wellcome Trust of the United Kingdom, will begin within months and run until 2015. Texas Biomed will conduct the experimental protocols with the animals and both Texas Biomed and UGA will conduct biomarker analysis.

Tarleton hopes this project will lead to discoveries that save lives and foster the creation of new treatments for this common and underserved disease.

"Identifying a method to accurately and efficiently determine treatment efficacy will increase utilization of existing therapies and will facilitate the discovery of new therapies," he said.

add to favorites email to friend print save as pdf

Related Stories

UGA animal vaccine may slow deadly spread of Chagas disease

Feb 16, 2012

Chagas disease is the single most common cause of congestive heart failure and sudden death in the world. The devastating parasitic infection affects millions of people throughout Central and South America. But as global ...

FDA approves new test for Chagas disease

Nov 26, 2011

The Food and Drug Administration has approved Abbott Laboratories' ESA test for Chagas disease, which could be a useful tool in protecting the nation's blood supply from contamination.

Major breakthrough in the diagnosis of parasitic diseases

Apr 27, 2010

Montreal, April 27, 2010 - Chagas disease is one of the most deadly parasitic diseases in the world. It affects more than 10 million people, primarily in the Americas. In South America alone it kills 50 000 people each year. ...

Recommended for you

Filipino tests negative for Middle East virus

10 hours ago

A Filipino nurse who tested positive for the Middle East virus has been found free of infection in a subsequent examination after he returned home, Philippine health officials said Saturday.

US orders farms to report pig virus infections

Apr 18, 2014

The U.S. government is starting a new program to help monitor and possibly control the spread of a virus that has killed millions of pigs since showing up in the country last year.

Foreigner dies of MERS in Saudi

Apr 18, 2014

A foreigner has died after she contracted MERS in the Saudi capital, the health ministry said on announced Friday, bringing the nationwide death toll to 73.

Vietnam battles fatal measles outbreak

Apr 18, 2014

Vietnam is scrambling to contain a deadly outbreak of measles that has killed more than 100 people, mostly young children, and infected thousands more this year, the government said Friday.

New clues on tissue scarring in scleroderma

Apr 18, 2014

A discovery by Northwestern Medicine scientists could lead to potential new treatments for breaking the cycle of tissue scarring in people with scleroderma.

User comments